Testosterone Replacement Therapy (TRT)

Medically supervised testosterone replacement therapy for men with confirmed low testosterone, covering initial consultation, baseline hormone blood panel, prescription of the appropriate TRT modality and structured follow-up monitoring to optimise dosing and confirm safety.

Testosterone replacement therapy (TRT) at Dr Tan Medical Center is a fully supervised programme designed for men experiencing the symptoms of andropause, hypogonadism or clinically low testosterone. Dr Tan Kok Kuan has over two decades of experience in men's hormonal health and takes a thorough, evidence-based approach that begins with establishing a clear clinical picture before any treatment is initiated. The programme starts with a detailed consultation in which the doctor takes a comprehensive history of symptoms — fatigue, reduced libido, erectile dysfunction, low mood, difficulty maintaining muscle mass, increased body fat — alongside a review of medications, lifestyle factors and relevant medical history. A baseline blood panel is ordered, measuring total testosterone, free testosterone, sex hormone-binding globulin (SHBG), luteinising hormone (LH), follicle-stimulating hormone (FSH), prolactin and oestradiol. Metabolic markers including fasting glucose, HbA1c, full lipid profile, liver enzymes and a full blood count are included, as are prostate-specific antigen (PSA) and haematocrit, which are important safety parameters once TRT commences. Once low testosterone is confirmed and secondary causes have been excluded, the doctor discusses the available treatment modalities. Daily testosterone gel (applied to the shoulder or upper arm) is a common first-line option for men who prefer a non-invasive approach and want the flexibility to adjust dosing more easily. Long-acting injectable testosterone undecanoate (Nebido), administered in clinic every 10 to 14 weeks, suits patients who prefer fewer interventions and consistently stable serum levels. The appropriate modality is chosen collaboratively based on the patient's lifestyle, preferences and clinical profile. Follow-up blood tests are scheduled at six to twelve weeks after initiation to assess hormone response, haematocrit rise, oestradiol levels and safety markers. If oestradiol climbs into a symptomatic range — a common occurrence in men with higher body fat — an aromatase inhibitor may be introduced. Once the patient is stable, ongoing monitoring typically occurs every three to six months. The clinic's transparent pricing philosophy means costs are discussed clearly at the outset, and the programme is designed to be sustained long-term with minimal friction.